

FOI REF: 21/552

15<sup>th</sup> November 2021

Tel: 0300 131 4500

Website: www.esht.nhs.uk

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

**Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?**

• Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single Agent	48
• Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	5
• Abemaciclib + Fulvestrant	0
• Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
• Atezolizumab +Nab-paclitaxel/Paclitaxel	0
• Capecitabine as a single agent	30
• Carboplatin or Cisplatin as a single agent	1
• Eribulin as a single agent or in combination	0
• Everolimus + Exemestane	1
• Fluorouracil	0
• Fulvestrant as a single agent	0
• Goserelin	-
• Lapatinib	0
• Neratinib	0
• Olaparib	0
• Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	29
• Palbociclib + Fulvestrant	16
• Pertuzumab + Trastuzumab + Docetaxel	7
• Platinum (e.g. carboplatin or cisplatin) as a single agent (Same as Carboplatin or Cisplatin as a single agent above)	1
• Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	8
• Ribociclib + Fulvestrant	5

• Talazoparib	0
• Tamoxifen	8
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	36
• Transtuzumab as a single agent	17
• Trastuzumab emtansine	15
• Transtuzumab deruxtecan	0
• Any other active systemic anti-cancer therapy	76

**Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?**

East Sussex Healthcare NHS Trust does not centrally record the information requested above. To enable the Trust to provide this information would require a manual review of patients' records.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department ([esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)  
 Corporate Governance Manager  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)